Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the...

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Guidelines recommend indefinite aspirin for atherothrombotic risk.
• Dual antiplatelet therapy (aspirin/clopidogrel) is more effective than aspirin alone for cardiovascular risk reduction in specific patient groups.
• Current recommendations often limit dual therapy duration to less than one year.

Purpose of the Study:

• To review the benefits and risks of long-term dual antiplatelet therapy.
• To examine the evidence for prolonged aspirin/clopidogrel use beyond one year.
• To identify areas requiring further clinical trials for optimal antiplatelet management.

Main Methods:

• Literature review of clinical trials and guidelines.
• Analysis of evidence regarding cardiovascular risk reduction with varying durations of dual antiplatelet therapy.
• Discussion of clinical scenarios necessitating early antiplatelet withdrawal.

Main Results:

• Dual antiplatelet therapy demonstrates superior efficacy over aspirin monotherapy.
• Evidence suggests potential benefits of prolonged dual therapy in certain patient populations.
• Uncertainty exists regarding optimal duration and management post-event-free periods or non-cardiac surgery.

Conclusions:

• Long-term dual antiplatelet therapy presents a complex balance of benefits and risks.
• Further clinical trials are essential to establish optimal treatment durations and guide clinical practice.
• Evidence-based guidance is needed for discontinuing clopidogrel and managing patients requiring non-cardiac surgery.